It refers to methods that control the relative flux through competing enzymatic steps in an engineered metabolic pathway, typically by adjusting enzyme expression ratios, precursor supply, or suppressing byproduct-forming branches. In patent terms this shows up as claims combining a host bacterial cell, a defined set of pathway enzymes, and a stated ratio or control mechanism rather than a single gene insertion. The search terms behind this dataset — metabolic flux, enzyme ratio, pathway bottleneck, precursor supply, byproduct suppression — map directly onto how these claims are drafted.

The assignee ranking covers 100 companies across the 234 records in scope, with the leader holding 32 records and the field concentrated at the top: the five largest filers together account for 38.9% of all 234 records, and the ten largest for 57.7%. Beyond that top group there is a long tail of single- or few-filing entrants, which is typical of a field still absorbing academic spinouts and smaller synthetic-biology companies alongside a handful of established players.

Filings rose through the late 2010s to a peak of 24 records in 2022, then eased to 17 by 2024 — an 11% decline across that 2021-to-2024 span. That should not be read as the field cooling, because publication lags filing by roughly 18 months, meaning 2025 and 2026 figures in any such dataset are still incomplete. The safest reading is a mature but still active filing base rather than a field in decline.